Article
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
The lancet. Gastroenterology & hepatology - 1 Nov 2016
Domingo Enric, Freeman-Mills Luke, Rayner Emily, Glaire Mark, Briggs Sarah, Vermeulen Louis, Fessler Evelyn, Medema Jan Paul, Boot Arnoud, Morreau Hans, van Wezel Tom, Liefers Gerrit-Jan, Lothe Ragnhild A, Danielsen Stine A, Sveen Anita, Nesbakken Arild, Zlobec Inti, Lugli Alessandro, Koelzer Viktor H, Berger Martin D, Castellví-Bel Sergi, Muñoz Jenifer, de Bruyn Marco, Nijman Hans W, Novelli Marco, Lawson Kay, Oukrif Dahmane, Frangou Eleni, Dutton Peter, Tejpar Sabine, Delorenzi Mauro, Kerr Rachel, Kerr David, Tomlinson Ian, Church David N
Abstract excerpt
BACKGROUND: Precision cancer medicine depends on defining distinct tumour subgroups using biomarkers that may occur at very modest frequencies. One such subgroup comprises patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POLE) proofreading. METHODS: We examined the association of POLE proofreading domain mutation with clinicopathological variables...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.